Current pharmacological treatment options for male lower urinary tract symptoms

2013 ◽  
Vol 14 (8) ◽  
pp. 1043-1054 ◽  
Author(s):  
Frank Strittmatter ◽  
Christian Gratzke ◽  
Christian G Stief ◽  
Petter Hedlund
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Pharmacological Treatment ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Tomasz Rechberger ◽  
Andrzej Wrobel ◽  
Alicja Zietek ◽  
Ewa Rechberger ◽  
Beata Kulik-Rechberger ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Pharmacological Treatment ◽  
Lower Urinary Tract ◽  
Midurethral Sling ◽  
Additional Treatment ◽  
Urinary Tract Symptoms ◽  
Before And After ◽  
Sling Placement ◽  
Lower Urinary

Aim. Lower urinary tract symptoms (LUTS) frequently affect patients immediately after midurethral sling (MUS) placement. The objective of the study was to assess if solifenacin or mirabegron decreases incidence of LUTS in women who underwent transobturator MUS. Methods. A prospective randomized trial was conducted on patients undergoing ambulatory transobturator midurethral sling due to stress urinary incontinence (SUI). All participants were questioned before and after surgery for occurrence of bothersome LUTS. A total of 328 patients who underwent transobturator MUS were randomly assigned to one of three groups: prophylaxis with 10 mg of solifenacin, prophylaxis with 50 mg of mirabegron, or without any additional treatment. LUTS evolution and efficacy of solifenacin and mirabegron were analyzed based on results of assessments made during follow-up visits at 1 and 6 weeks after surgery. Comparison of the prevalence of LUTS was done using chi2 test. Results. Prevalence of urgency and frequency episodes increased notably 1 week after sling placement and then came down to baseline levels. Solifenacin and mirabegron significantly reduced the incidence of urgency after 1 week, but after 6 weeks the beneficial effect was observed only in case of solifenacin. Treatment with mirabegron reduced the percentage of patients suffering from frequency after 6 weeks. Although prevalence of nocturia did not raise after sling placement, both treatments significantly reduced the incidence of this complaint after 6 weeks. Pharmacological treatment did not modulate the course of hesitancy and terminal dribbling. Conclusions. Treatment with solifenacin or mirabegron may significantly reduce the incidence of undesired LUTS after MUS.

scholarly journals Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base

2017 ◽  
Vol 10 (2) ◽  
pp. 79-92 ◽  
Author(s):  
Mauro Gacci ◽  
Arcangelo Sebastianelli ◽  
Pietro Spatafora ◽  
Giovanni Corona ◽  
Sergio Serni ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Treatment Options ◽  
Specific Recommendation ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Voiding Symptoms ◽  
Urinary Tract Symptoms ◽  
Detailed Medical History ◽  
Lower Urinary

Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, pelvic ischemia, prostatic chronic inflammation and associated comorbidities in the pathophysiology of storage LUTS. A detailed evaluation of the severity of storage LUTS, and the concomitance of these symptoms with voiding and postmicturition symptoms, is mandatory for improving the diagnosis and personalizing treatment. A detailed medical history with comorbidities and associated risk factors, a physical examination, a comprehensive analysis of all the features of LUTS, including their impact on quality of life, and a frequency–volume chart (FVC) or bladder diary, are recommended for men with storage LUTS. Several drugs are available for the treatment of LUTS secondary to benign prostatic obstruction (BPO). Alpha-blockers (α-blockers), 5-α-reductase inhibitors and phosphodiesterase type 5 inhibitors are commonly used to manage storage LUTS occurring with voiding symptoms associated with BPO. Muscarinic receptor antagonists and Beta 3-agonists (β3-agonists) alone, or in combination with α-blockers, represent the gold standard of treatment in men with predominant storage LUTS. There is no specific recommendation regarding the best treatment options for storage LUTS after prostatic surgery.

Sign in / Sign up

Export Citation Format

Share Document